Monday, September 17, 2012

Rempex Pharma - Targeting Antibiotic Resistance



Resistance to antibiotics including the last line anitbiotics - carbapenem has become a bothering issue and . The  Gram-negative bacteria generate resistance to carbapenems by producing a variety of beta lactamases called carbapenemases that inactivate carbapenems.  Rempex Pharmaceuticals Inc. has designed a beta lactamase inhibitor that restored carbapenem activity in preclinical models and could be effective against multi-drug resistant Gram-negative bacteria.
At the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco Rempex presented preclincial data on RPX2003. RPX2003 is combination of  a carbapenem antibiotic with an inhibitor of carbapenemases. RX2003 demonstrated activity against Gram-negative pathogens including Escherichia coli and Pseudomonas aeruginosa and in strains with resistance caused by Klebsiella Pneumoniae (KPC). KPC is one of the hardest carabpenemases to inhibit.